Furthermore, in a parallel comparison assay, SCR-6852 displayed greater capabilities in ERα degradation and anti-proliferation than 4-OHT and AZD-9496 in multiple ER + breast cancer cell lines, indicating SCR-6852 was different from 4-OHT or AZD-9496 and similar with Fulvestrant. This evidence concerns the gene ESR1 and breast cancer.